KR : Samsung Biologics - More than just Moderna

We do not see its contract with Moderna for the fill-and-finish of the latter’s mRNA Covid-19 vaccine as a key catalyst for near-term earnings growth. Driven Plant 3’s ramp-up (utilisation ≥ 75%) and high pre-order demand for Plant 4 (22 RFPs), we project 16% FY21-26F sales CAGR (OPM: 28-30%). Reiterate Add with a higher DCF-based target price of W1,000,000. This note marks the transfer of coverage to Jiwon Lee.

Most Viewed See latest

This publication is being distributed by Tellimer solely for information purposes irrespective of a particular user's means, financial situation or investment objectives. The information does not con...

Full Tellimer disclaimers